Novartis (Switzerland)

Development and testing of a general amber force field

Abstract We describe here a general Amber force field (GAFF) for organic molecules. GAFF is designed to be compatible with existing Amber force fields for proteins and nucleic a...

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

Abstract Objective The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been...

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent ...

Markov Chain Monte Carlo in Practice

In a family study of breast cancer, epidemiologists in Southern California increase the power for detecting a gene-environment interaction. In Gambia, a study helps a vaccinatio...

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients wit...

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT s...

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

Next-generation characterization of the Cancer Cell Line Encyclopedia

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had rec...